Search Results - "D'Onofrio, Loretta"
-
1
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence
Published in Journal of cellular physiology (01-11-2020)“…Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic…”
Get full text
Journal Article -
2
New molecular insights in tobacco-induced lung cancer
Published in Future oncology (London, England) (01-05-2013)“…We know that cigarette smoking is a leading preventable cause of carcinogenesis in lung cancer. Cigarette smoke is a mixture of more than 5000 chemical…”
Get more information
Journal Article -
3
Classic Kaposi Sarcoma: to treat or not to treat?
Published in BMC research notes (10-04-2015)“…Classic Kaposi Sarcoma (KS) is vascular sarcoma, known to be more common in Mediterranean elderly men and characterized by an indolent clinical behavior. To…”
Get full text
Journal Article -
4
Pazopanib and pancreatic toxicity: a case report
Published in BMC research notes (14-05-2015)“…Pazopanib is an oral multitargeted tyrosine-kinase inhibitor, used as a single agent to treat advanced renal cell carcinoma. Treatment with other…”
Get full text
Journal Article -
5
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
Published in PloS one (31-07-2015)“…The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently…”
Get full text
Journal Article -
6
Triple positive breast cancer: A distinct subtype?
Published in Cancer treatment reviews (01-02-2015)“…Highlights • HER-2, ER and PgR have a key role in treatment decision making in breast cancer. • Triple positive (TP) tumours exhibit a unique clinical and…”
Get full text
Journal Article -
7
Denosumab for cancer-related bone loss
Published in Expert opinion on biological therapy (01-11-2020)“…Prolonged use of anti-cancer treatments in breast and prostate tumors alters physiological bone turnover leading to adverse skeletal related events, such as…”
Get more information
Journal Article -
8
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
Published in Scientific reports (06-09-2017)“…Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose…”
Get full text
Journal Article -
9
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Published in Cancer biology & therapy (01-02-2019)“…We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment…”
Get full text
Journal Article -
10
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
Published in Breast cancer research : BCR (02-09-2015)“…Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the…”
Get full text
Journal Article -
11
Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series
Published in Future oncology (London, England) (01-05-2017)“…During the last decades, much effort has been made to develop and test treatments for advanced/metastatic breast cancer (MBC) able to prolong survival and…”
Get full text
Journal Article -
12
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Published in Oncotarget (22-08-2017)“…We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in…”
Get full text
Journal Article -
13
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome
Published in Oncotarget (05-04-2016)“…We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both…”
Get full text
Journal Article -
14
Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
Published in Hepatic oncology (01-01-2016)“…Gall bladder cancer (GBC), and intrahepatic and extrahepatic (perihilar or distal bile duct's) cholangiocarcinomas (CCA) are usually diagnosed in locally…”
Get full text
Journal Article -
15
Abstract P5-14-01: Eribulin tolerability and correlation between neuropathy and a set of polymorphisms in metastatic breast cancer patients. Results from the PAINTER (Polymorphism And Incidence of Toxicity in ERibulin treatment) study
Published in Cancer research (Chicago, Ill.) (15-02-2020)“…BACKGROUND: Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses mainly on prolonging patients (pts) survival and improving their…”
Get full text
Journal Article -
16
Clinical features of male breast cancer and multimodal treatment: a comment to retrospective survey analysis at Italian centers
Published in Tumori (01-07-2014)Get full text
Journal Article -
17
Correlation between NDRG1 gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment)
Published in Journal of clinical oncology (20-05-2019)“…Abstract only 3116 Background: MBC is an incurable disease and therefore treatment focuses mainly on prolonging pts survival and improving quality of life…”
Get full text
Journal Article -
18
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
Published in International journal of cancer (01-04-2020)“…We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers…”
Get full text
Journal Article -
19
Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study
Published in Journal of clinical oncology (20-05-2017)“…Abstract only e12504 Background: Pertuzumab (P) , Trastuzumab (T) and Docetaxel (D) is standard first-line treatment in patients (pts) with HER2 + metastatic…”
Get full text
Journal Article -
20
Moving from the CLEOPATRA study to real life: Results from the G.O.N.O. SUPER trial
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article